| Eplerenone gains in mild HF cut across high-risk subgroups: EMPHASIS-HF - TheHeart.Org |
|
|
TheHeart.Org Paris, France - Even patients with such high-risk features as diabetes or renal compromise showed highly significant drops in CV mortality or heart-failure hospitalizations from treatment with eplerenone (Inspra, Pfizer) in EMPHASIS-HF, |